Analytical Approach to Changing EEG Education: Fabio Nascimento, MD
The clinical fellow at Massachusetts General Hospital provided background on his efforts to raise awareness of inconsistencies with EEG education in neurology residency programs.
Focal Seizures: Post-hoc Analysis of Cenobamate
Challenges of Treating Chronic Insomnia: Jennifer Martin, PhD
The AASM board of directors member and professor of medicine at UCLA also discussed the relative inefficacy of sleep hygiene therapy for insomnia.
Cladribine for Treatment of RMS
ELEKTRA Study in Dravet and Lennox-Gastaut Syndromes
Pavel Klein, MD: Determining Likelihood of Efficacy and AEs in Patient Populations
The director of the Mid-Atlantic Epilepsy and Sleep Center discussed his team’s investigations into predicting responders and adverse events.
Richard B. Lipton, MD: Achieving Simultaneous Acute and Preventive Migraine Treatment
The director of the Montefiore Headache Center discussed how his team’s findings can change the way physicians think about treating migraine.
Anti-CD20 Monoclonal Antibodies for Treatment of RMS
The Role of Developing Agents in Acute Migraine Paradigm
CGRP Receptor Agonists: Safety and Efficacy
5-HT1F Agonist Toxicity Profile and Role in Paradigm
The Significance of 5-HT1F Agonist Approval
Recent Approvals for Acute Migraine
The Importance of Patient Communication
Therapy Assessment: Pain Relief & Onset Monitorization
Acute Migraine Treatment: Pain Freedom and Guidelines
Goals of and Recommended Approach for Acute Treatment
Acute Migraine Management: Overview and Unmet Needs
Safety and Efficacy of CBD in Patients With TSC
William Rosenfeld, MD: Reducing Concomitant ASM Dosages for Focal Seizures
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed the different medications that cenobamate was used with.
Raymond Sanchez, MD: Phase 2 Trial Data of Tavapadon in Parkinson Disease
The chief medical officer of Cerevel Therapeutics detailed phase 2 data of its investigational agent tavapadon, which has been studied in patients with Parkinson disease.
Donanemab Shows Decline in Alzheimer, Pfizer DMD Study Launched, REM Not Correlated With Seizures
Neurology News Network for the week ending January 16, 2021.
Strategies for Choosing Initial Therapy in MS
Clinical Benefit of Fenfluramine in Dravet Syndrome
Brian Wainger, MD, PhD: Momentum Within the ALS Treatment Landscape
The assistant professor of neurology and anesthesiology at Harvard Medical School discussed the landscape of ALS treatments and his outlook on how the future might evolve.
Leo Petrossian, PhD, MBA: Accelerating Optimization of Epilepsy Management
The CEO of Nile AI spoke to how the newly founded company plans to develop data science techniques to improve the optimization of epilepsy care and management.
Phase 4 ELEVATE Study
Richard B. Lipton, MD: CGRP Receptor-Targeting in the Prevention of Migraine
The director of the Montefiore Headache Center discussed the current landscape of migraine treatments.
OPTIMUM Phase 3 Trial: Secondary End Point Effect on Fatigue
Michael Okun, MD: Long-Term Plan for Modifying Neurologic Device Approval System
The executive director of the Norman Fixel Institute for Neurological Diseases gave his call-to-action on how to change the approval system for neurologic devices for rare diseases.
